©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2017; 23(47): 8437-8438
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8437
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8437
Silymarin: An option to treat non-alcoholic fatty liver disease
Carmela Colica, CNR, IBFM UOS of Germaneto, University “Magna Graecia”, Catanzaro 88100, Italy
Luigi Boccuto, Research Department, Greenwood Genetic Center, School of Health Research, Clemson University, Greenwood 29646, United States
Ludovico Abenavoli, Department of Health Sciences, University Magna Græcia, Campus Germaneto, Viale Europa, Catanzaro 88100, Italy
Author contributions: Colica C and Abenavoli L performed research of literature data and wrote the paper; Boccuto L revised the paper.
Conflict-of-interest statement: Authors declares no conflict of interest related to this publication.
Correspondence to: Ludovico Abenavoli MD, PhD, Associate Professor, Department of Health Sciences, University Magna Græcia, Campus Germaneto, Viale Europa - Germaneto, Catanzaro 88100, Italy. l.abenavoli@unicz.it
Telephone: +39-961-3697113 Fax: +39-961-754220
Received: November 8, 2017
Peer-review started: November 9, 2017
First decision: November 21, 2017
Revised: November 27, 2017
Accepted: December 4, 2017
Article in press: December 4, 2017
Published online: December 21, 2017
Processing time: 41 Days and 17.7 Hours
Peer-review started: November 9, 2017
First decision: November 21, 2017
Revised: November 27, 2017
Accepted: December 4, 2017
Article in press: December 4, 2017
Published online: December 21, 2017
Processing time: 41 Days and 17.7 Hours
Core Tip
Core tip: Supplementation of silymarin in association with an hypocaloric diet and physical activity, can be a correct approach to treat patients with non-alcoholic fatty liver disease in clinical practice.